These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 32967849)

  • 1. Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19).
    McCullough PA
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32967849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series.
    Fu D; Cao R; Zhao L; Li W; Zhong W; Wen J
    Crit Care; 2020 Sep; 24(1):578. PubMed ID: 32977854
    [No Abstract]   [Full Text] [Related]  

  • 3. Repurposing Therapeutics for Potential Treatment of SARS-CoV-2: A Review.
    Santos J; Brierley S; Gandhi MJ; Cohen MA; Moschella PC; Declan ABL
    Viruses; 2020 Jun; 12(7):. PubMed ID: 32629804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
    Martinez MA
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Favipiravir, an antiviral for COVID-19?
    Coomes EA; Haghbayan H
    J Antimicrob Chemother; 2020 Jul; 75(7):2013-2014. PubMed ID: 32417899
    [No Abstract]   [Full Text] [Related]  

  • 6. A Favipiravir-induced Fever in a Patient with COVID-19.
    Kurita T; Ishida K; Muranaka E; Sasazawa H; Mito H; Yano Y; Hase R
    Intern Med; 2020; 59(22):2951-2953. PubMed ID: 33191372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic Review on Repurposing Use of Favipiravir Against SARS-CoV-2.
    Nasir M; Perveen RA; Saha SK; Talha KA; Selina F; Islam MA
    Mymensingh Med J; 2020 Jul; 29(3):747-754. PubMed ID: 32844821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition.
    Takahashi H; Iwasaki Y; Watanabe T; Ichinose N; Okada Y; Oiwa A; Kobayashi T; Moriya M; Oda T
    Int J Infect Dis; 2020 Nov; 100():283-285. PubMed ID: 32829044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protease Inhibitors: Candidate Drugs to Inhibit Severe Acute Respiratory Syndrome Coronavirus 2 Replication.
    Yamaya M; Nishimura H; Deng X; Kikuchi A; Nagatomi R
    Tohoku J Exp Med; 2020 May; 251(1):27-30. PubMed ID: 32448818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) co-infection with HIV: clinical case series analysis in North Central Nigeria.
    Akyala AI; Iwu CJ
    Pan Afr Med J; 2020; 37():47. PubMed ID: 33209174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019.
    Hase R; Kurata R; Ishida K; Kurita T; Muranaka E; Mito H
    Intern Med; 2020 Sep; 59(18):2327-2329. PubMed ID: 32727996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Gene-Eden-VIR and Novirin on SARS-CoV: Implications for COVID-19.
    Polansky H; Lori G
    J Evid Based Integr Med; 2020; 25():2515690X20932523. PubMed ID: 32551855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis.
    Shrestha DB; Budhathoki P; Khadka S; Shah PB; Pokharel N; Rashmi P
    Virol J; 2020 Sep; 17(1):141. PubMed ID: 32972430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of antiviral activity of darunavir against SARS-CoV-2.
    De Meyer S; Bojkova D; Cinatl J; Van Damme E; Buyck C; Van Loock M; Woodfall B; Ciesek S
    Int J Infect Dis; 2020 Aug; 97():7-10. PubMed ID: 32479865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review.
    Vargas M; Servillo G; Einav S
    Eur Rev Med Pharmacol Sci; 2020 Aug; 24(16):8592-8605. PubMed ID: 32894567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity.
    Kaptein SJF; Jacobs S; Langendries L; Seldeslachts L; Ter Horst S; Liesenborghs L; Hens B; Vergote V; Heylen E; Barthelemy K; Maas E; De Keyzer C; Bervoets L; Rymenants J; Van Buyten T; Zhang X; Abdelnabi R; Pang J; Williams R; Thibaut HJ; Dallmeier K; Boudewijns R; Wouters J; Augustijns P; Verougstraete N; Cawthorne C; Breuer J; Solas C; Weynand B; Annaert P; Spriet I; Vande Velde G; Neyts J; Rocha-Pereira J; Delang L
    Proc Natl Acad Sci U S A; 2020 Oct; 117(43):26955-26965. PubMed ID: 33037151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug Discovery Strategies for SARS-CoV-2.
    Shyr ZA; Gorshkov K; Chen CZ; Zheng W
    J Pharmacol Exp Ther; 2020 Oct; 375(1):127-138. PubMed ID: 32723801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Azithromycin added to hydroxychloroquine for patients admitted to intensive care due to coronavirus disease 2019 (COVID-19)-protocol of randomised controlled trial AZIQUINE-ICU.
    Duška F; Waldauf P; Halačová M; Zvoníček V; Bala J; Balík M; Beneš J; Klementová O; Kozáková I; Kubricht V; Le Roy A; Vymazal T; Řehořová V; Černý V;
    Trials; 2020 Jul; 21(1):631. PubMed ID: 32641163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to "Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2".
    Du YX; Chen XP
    Clin Pharmacol Ther; 2020 Aug; 108(2):190. PubMed ID: 32353191
    [No Abstract]   [Full Text] [Related]  

  • 20. Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2.
    Eloy P; Solas C; Touret F; Mentré F; Malvy D; de Lamballerie X; Guedj J
    Clin Pharmacol Ther; 2020 Aug; 108(2):188. PubMed ID: 32350860
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 24.